PubMed Health⌕ Search

Biomedical subjects

M Israel

Publications and source records attributed to M Israel.

At least 145 records · Page 8Linked to original sources
PubMed1978

Effect of adriamycin and analogs on the nuclear fluorescence of propidium iodide-stained cells.

Adriamycin (ADR) and N-trifluoroacetyladriamycin-14-valerate, respectively, inhibit and enhance the nuclear fluorescence of cells stained with propidium iodide for DNA per cell estimation by flow cytometry. In cells incubated with ADR, the reduction in fluorescence is gradually manifested due to the slow intracellular drug transport. In contrast the effect of N-trifluoroacetyladriamycin-14-valerate on propidium iodide nuclear fluorescence is seen within 5 min of incubation. The effect of ADR on propidium iodide nuclear fluorescence could be detected in vivo even after 24 hr of ADR administration.

Animals↗
PubMed1977

Isolation of pure cholinergic nerve endings from Torpedo electric organ. Evaluation of their metabolic properties.

Pure cholinergic nerve endings (synaptosomes) were isolated from the electric organ of Torpedo by a rapid procedure. These synaptosomes are approximately 3 micron in diameter. They contain an occasional mitochondrion, numerous synaptic vesicles, and sometimes an active zone is observed. No postynaptic membrane attachment is found. This nerve ending fraction is extremely pure as shown by morphological controls and biochemical data. It is rich in choline acetyltransferase (450 nmol/h per mg protein) and acetylcholine (ACh) (130 nmol/mg protein). The isolated endings retain their cytoplasmic components and they synthesize ACh and are stable in vitro for several hours, as shown by biochemical measurements and morphological analysis.

Acetylcholine↗
PubMed1977

A mathematical model of a blood-gas service.

A mathematical model depicting operation of a blood-gas workstation was developed by two systems analysts working closely with two clinical pathologists. This model was used to provide estimates of average as well as maximum turnaround times under various conditions of workload, specimen types (capillary vs. syringe), methodology (use of IL 513 vs. IL 313 for capillary samples), and reporting procedures (report each sample as analyzed vs. report after analysis of all samples in batch). These estimates have been validated against actual experience in our laboratory. Such an objective mathematical model can be used to plan optimal service.

Blood Gas Analysis↗
PubMed1976

A worksheet summary system for clinical laboratory management.

This article describes a simple method for summarizing total activity from the worksheets used at each workstation in a clinical laboratory. Monthly reports display day-to-day trends in total workload, as well as changes in the ratio between charged and total tests. Cumulative summaries of the monthly reports display month-to-month trends of total workload, as well as the ratio between charged and total tests. These reports also provide: (1) a simple method to calculate "lost revenue" (difference between total "chargeable" work and credited revenue); (2) more rapid and more uniform calculation of CAP workload units. In the author's laboratory, time required to maintain this data base and calculate CAP workload units has been less than the time previously required for calculation of CAP workload units alone.

Cost-Benefit Analysis↗
PubMed1976

Differences in cellular uptake and cytofluorescence of adriamycin and N-trifluoroacetyladriamycin-14-valerate.

Adriamycin-specific fluorescence appears slowly in living cells and is localized in nuclei and chromosomes. N-Trifluoroacetyladriamycin-14-valerate, a recently synthesized adriamycin analog, differs from the parent anthracycline in the rapid appearance of its fluorescence in the cytoplasm of living cells and the lack of any fluorescent binding to nuclei and chromosomes.

Cell Line↗
PubMed1975

N-trifluoroacetyladriamycin-14-valerate, an analog with greater experimental antitumor activity and less toxicity than adriamycin.

N-Trifluoroacetyladriamycin-14-valerate (AD 32), an analog of adriamycin, exhibits significantly greater antitumor activity than does adriamycin or daunorubicin in two experimental mouse tumor systems under similar assay conditions (C57BL X DBA/2 F1 male mice, agents administered i.p. each day for Days 1 to 4). Against the P388 leukemia at optimal dosages, AD 32 gave a +429% increase in median life-span with 3 of 5 60-day survivors compared to +132% for adriamycin (no 30-day survivors). In the L1210 leukemia system, AD 32 at several dosages consistently and reproducibly effected an increase in lifespan in excess of 445%, with a high percentage of 60+-day survivors compared to adriamycin (+42 to +54% ILS; no 30-day survivors). The reduced toxicity of AD 32 was evidenced by its optimal dose range, which is significantly greater than the lethal dose for 100% of mice of adriamycin, and by its lack of delayed toxicity. In vitro, AD 32 was somewhat less effective than was adriamycin in inhibiting the growth of CCRF-CEM cells; enzymatic conversion of AD 32 by cell-free culture medium was not observed. The unique growth-inhibitory properties of this analog indicate that the therapeutic effectiveness of the anthracycline antitumor antibiotics can be retained or enhanced by substitution on the glycosidic amino group.

Animals↗